To identify a set of genes whose expression is regulated by cetuximab treatment in colorectal cancer cells harboring KRAS activating mutation, we first established xenograft mouse models with KRASG12D mutation-bearing LS174T cells, which was chosen as a representative colon cancer cell line for this study. This evidence concerns the gene KRAS and malignant colon neoplasm.